Abstract 2820
Background
Fine-needle aspiration biopsy (FNAB) is the standard diagnostic method of thyroid nodules. However, a fraction of the cytology assessments generates indeterminate results. Our group developed a method based on the relative quantification of three transcripts to aid the diagnosis of thyroid lesions. In this study, we aimed to validate the performance and applicability of this diagnostic test in FNAB.
Methods
Seventy-five prospectively collected FNAB were evaluated for CLDN10, HMGA2 and LAMB3 gene expression (EIF2B1 as reference gene) by RT-qPCR, using the leftover cells inside the needles. A mathematical model previously established was applied and the scores were compared with the Bethesda categories and the final postoperative report.
Results
We demonstrated the feasibility of the molecular test, even with very small yields of RNA. The three genes tested showed higher expression in the conclusive malignant cases (15 Bethesda VI) in relation to the conclusive benign nodules (35 Bethesda II). The application of the diagnostic algorithm allowed the distinction of these samples with 93% sensitivity (14/15) and 100% specificity (35/35). Among the patient with indeterminate nodules (Bethesda III-V), the test was able to correctly discriminate malignant from benign nodules with 71% sensitivity (5/7 tumors) and 100% specificity (4/4 benign lesions). Fourteen indeterminate cases are being followed-up and were not submitted to surgery to date. Furthermore, we observed that larger tumors (>1 cm), presenting lymph node metastasis and extrathyroidal extension were associated with higher algorithm scores (total of 22 malignant cases).
Conclusions
A thyroid diagnostic method based on the analysis of only four genes by RT-qPCR (3 targets and 1 reference) revealed high accuracy and applicability even in very limited FNAB material, presenting also a potential prognostic role.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FAPESP.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5629 - Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumor infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion
Presenter: Luca Campedel
Session: Poster Display session 2
Resources:
Abstract
5792 - A novel PET parameter for cancer stem cell metabolism: early prediction of chemosensitivity to neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Chanwoo Kim
Session: Poster Display session 2
Resources:
Abstract
3728 - Using nodal ratio to predict recurrence in patients with 4 or more positive lymph nodes early stage breast cancer
Presenter: Besma Graja
Session: Poster Display session 2
Resources:
Abstract
3395 - Re-sentinel node biopsy for local recurrence after breast-conserving surgery
Presenter: Yuka Matsubara
Session: Poster Display session 2
Resources:
Abstract
4302 - Assessment of prognostic and therapeutic factors in men with breast cancer
Presenter: Daniel Herrero Rivera
Session: Poster Display session 2
Resources:
Abstract
4263 - Genomic Profiling of Chinese Breast Cancer Patients
Presenter: Zhonghua Tao
Session: Poster Display session 2
Resources:
Abstract
2406 - Genome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
Presenter: Naomi Walsh
Session: Poster Display session 2
Resources:
Abstract
2575 - Next-generation DNA Sequencing (NGS) Results for Tumors From Phase 2 ABRAZO Study of Talazoparib After Platinum or Cytotoxic Non-Platinum Regimens in Patients (pts) With Advanced Breast Cancer (ABC) and Germline BRCA1/2 (gBRCA) Mutations
Presenter: Nicholas C. Turner
Session: Poster Display session 2
Resources:
Abstract
4499 - FGFR1 and CCND1 gene amplifications are associated with breast cancer resistance to aromatase inhibitors
Presenter: Evgeny Imyanitov
Session: Poster Display session 2
Resources:
Abstract
4110 - Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe Experience
Presenter: Sercan Aksoy
Session: Poster Display session 2
Resources:
Abstract